{"entity":{"id":"nct06057610","kind":"trial","name":"A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer","aka":[],"tldr":"A phase 3 trial of Trastuzumab rezetecan, Pertuzumab, Docetaxel and Trastuzumab in HER2-positive breast cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.","summary":"A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT06057610 by Jiangsu HengRui Medicine Co., Ltd., with 868 participants enrolled, started 2023-11-01 and due to reach its primary completion in 2026-07-15. Interventions recorded: SHR-A1811 Injection, SHR-A1811 Injection ； Pertuzumab Injection and Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06057610","url":"https://clinicaltrials.gov/study/NCT06057610"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-rezetecan","pertuzumab","docetaxel","trastuzumab"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06057610","phase":"3","setting":"A Phase III Multicenter, Randomized, Open-label, Active-Controlled Study of SHR-A1811 With or Without Pertuzumab Versus Trastuzumab, Pertuzumab and Docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","enrolled":868,"outcomes":[]},"route":"/trials/nct06057610/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}